Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]

Status:

Topic selection

Technology type:

Medicine

Decision:

Selected

Reason for decision:

Not eligible for Health Technology Evaluation guidance

Further information:

The NICE-Wide Prioritisation Board and NHS England have agreed that a Technology Appraisal (TA) would not be appropriate for this product and recommended that it is not selected for evaluation. Decision makers concluded that the clear rationale to not select is due to being a paediatric licence extension of the published adult TA456. NHS England will commission treatments for patients aged less than 18 years where specific commissioning conditions are met as per the Commissioning medicines for children in specialised services policy.

ID number:

11955

Project Team

Project lead

Danielle Lees

Email enquiries

If you have any queries please email [email protected]

Timeline

Key events during the development of the guidance:

For further information on how we select topics for development, please see our page about prioritising our guidance topics